Roche, Hansoh to Develop Antibody-Drug Conjugates — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Hansoh said yesterday it struck a massive deal with Roche.
- Roche’s agreement with Hansoh is to develop a portfolio of antibody-drug conjugates.
Why it matters: Announced yesterday, Roche’s collaboration with Hansoh makes its China drug search concrete: a portfolio of antibody-drug conjugates. Hansoh is the named Chinese pharmaceutical counterparty, while the available excerpt discloses no candidate names, financial terms, trial dates, deal value or development assignments.
Ask SkimNews
